Powering the Next Wave of Precision Genetic Medicines — Together
We believe in winning together and importantly, winning in our shared mission to help more patients in need.
Our goal is to maximize the potential of our SORT LNP delivery technology even beyond those rare diseases in our pipeline so that more patients may realize the full benefit of genetic medicines.
“We can enhance the potency of any genetic cargo by packaging it using our SORT LNP platform and delivering it directly to the organs and cells impacted by disease. This creates vast opportunities to address a wide range of medical needs not possible with current technologies.”
Shehnaaz Suliman, M.D., M.B.A., M.Phil.
Chief Executive Officer
-
Strategic Investment from the Cystic Fibrosis FoundationStrategic Investment from the Cystic Fibrosis Foundation
-
Strategic Collaboration Explores Single Vector Gene-Editing PlatformStrategic Collaboration Explores Single Vector Gene-Editing Platform
Do you want to be on the frontier of a new generation of precision genetic medicines?
Contact us at [email protected]
Where to find ReCode this month:
September 4, 2024
New York City
Morgan Stanley Healthcare Conference
We’re honored to participate in the Morgan Stanley Healthcare Conference in New York City from September 4 – 6. We extend our gratitude to the organizers for hosting this event.
Shehnaaz Suliman, our CEO, and Erica Jefferson, SVP, Corporate Affairs, will be in attendance. We look forward to engaging discussions and collaborations that shape the future of biotechnology. See you in New York City!
Read More
September 4, 2024
San Diego, CA
RNA Leaders USA Congress
We’re gearing up to attend the RNA Leaders USA Congress from September 4 – 5 in San Diego, CA. This conference is an essential gathering for professionals dedicated to the future of mRNA therapies. We look forward to speaking on our advancements and learning from the wealth of knowledge presented by experts in the field.
Read More
May 5, 2024
Glasgow, UK
47th European Cystic Fibrosis Conference
We look forward to attending the 47th European Cystic Fibrosis Conference in Glasgow from June 5 – 8. We welcome this opportunity to discuss RCT2100, our clinical-stage candidate in development to treat the 10-13% of CF patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators.
Read More
May 23, 2024
Virtual Event
Virtual Piper Sandler Lung Day Post-ATS
Read More
May 17, 2024
San Diego, CA
American Thoracic Society: Respiratory Innovation Summit
Read More
May 14, 2024
Boston, MA
TIDES USA 2024
Read More
